Advertisement

Journal of General Internal Medicine

, Volume 34, Issue 12, pp 2833–2841 | Cite as

Commercialization of User Data by Developers of Medicines-Related Apps: a Content Analysis

  • Quinn GrundyEmail author
  • Kellia Chiu
  • Lisa Bero
Original Research

Abstract

Background

Developers of medicines-related apps collect a variety of technical, health-related, and identifying user information to improve and tailor services. User data may also be used for promotional purposes. Apps, for example, may be used to skirt regulation of direct-to-consumer advertising of medicines. Researchers have documented routine and extensive sharing of user data with third parties for commercial purposes, but little is known about the ways that app developers or “first” parties employ user data.

Objective

We aimed to investigate the nature of user data collection and commercialization by developers of medicines-related apps.

Approach

We conducted a content analysis of apps’ store descriptions, linked websites, policies, and sponsorship prospectuses for prominent medicines-related apps found in the USA, Canada, Australia, and UK Google Play stores in late 2017. Apps were included if they pertained to the prescribing, administration, or use of medicines, and were interactive. Two independent coders extracted data from documents using a structured, open-ended instrument. We performed open, inductive coding to identify the range of promotional strategies involving user data for commercial purposes and wrote descriptive memos to refine and detail these codes.

Key Results

Ten of 24 apps primarily provided medication adherence services; 14 primarily provided medicines information. The majority (71%, 17/24) outlined at least one promotional strategy involving users’ data for commercial purposes which included personalized marketing of the developer’s related products and services, highly tailored advertising, third-party sponsorship of targeted content or messaging, and sale of aggregated customer insights to stakeholders.

Conclusions

App developers may employ users’ data in a feedback loop to deliver highly targeted promotional messages from developers, and commercial sponsors, including the pharmaceutical industry. These practices call into question developers’ claims about the trustworthiness and independence of purportedly evidenced-based medicines information and may create a risk for mis- or overtreatment.

Notes

Acknowledgments

The authors would like to acknowledge Chris Klochek, MSc, for developing the app store crawling program.

Funding

This work was funded by a grant from the Sydney Policy Lab at The University of Sydney. Quinn Grundy was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Supplementary material

11606_2019_5214_MOESM1_ESM.pdf (490 kb)
ESM 1 (PDF 490 kb)

References

  1. 1.
    Mobasheri MH, King D, Johnston M, Gautama S, Purkayastha S, Darzi A. The ownership and clinical use of smartphones by doctors and nurses in the UK: a multicentre survey study. BMJ Innov. 2015;1(4):174–181.CrossRefGoogle Scholar
  2. 2.
    Ahmed I, Ahmad NS, Ali S, et al. Medication adherence apps: Review and content analysis. JMIR mHealth uHealth. 2018;6(3):e62.CrossRefGoogle Scholar
  3. 3.
    Wilson D. Drug ap comes free, ads included. The New York Times. July 29, 2011: B1.Google Scholar
  4. 4.
    World Health Organization (WHO). Ethical criteria for medicinal drug promotion. Geneva: WHO;1988.Google Scholar
  5. 5.
    Parker L, Williams J, Bero L. Ethical drug marketing criteria for the 21st century. BMJ. 2018;361:k1809.CrossRefGoogle Scholar
  6. 6.
    Ebeling M. ‘Get with the Program!’: Pharmaceutical marketing, symptom checklists and self-diagnosis. Soc Sci Med. 2011;73(6):825–832.CrossRefGoogle Scholar
  7. 7.
    Dehling T, Gao F, Schneider S, Sunyaev A. Exploring the far side of mobile health: Information security and privacy of mobile health apps on iOS and Android. JMIR Mhealth Uhealth. 2015;3(1):e8.CrossRefGoogle Scholar
  8. 8.
    Vallina-Rodriguez N, Sundaresan S, Razaghpanah A, et al. Tracking the trackers: Towards understanding the mobile advertising and tracking ecosystem. 1st Data and Algorithm Transparency Workshop; 2016; New York, NY.Google Scholar
  9. 9.
    Razaghpanah A, Nithyanand R, Vallina-Rodriguez N, et al. Apps, Trackers, privacy, and regulators: A global study of the mobile tracking ecosystem. Proceedings 2018 Network and Distributed System Security Symposium; 2018.Google Scholar
  10. 10.
    Binns R, Lyngs U, Van Kleek M, Zhao J, Libert T, Shadbolt N. Third party tracking in the mobile ecosystem. Proceedings of the 10th ACM Conference on Web Science - WebSci '18; 2018.Google Scholar
  11. 11.
    Grundy Q, Held F, Bero L. Tracing the potential flow of consumer data: A network analysis of prominent health and fitness apps. J Med Internet Res. 2017;19(6):e233.CrossRefGoogle Scholar
  12. 12.
    Huckvale K, Prieto J, Tilney M, Benghozi P-J, Car J. Unaddressed privacy risks in accredited health and wellness apps: a cross-sectional systematic assessment. BMC Med. 2015;13(1):214.CrossRefGoogle Scholar
  13. 13.
    Papageorgiou A, Strigkos M, Politou E, Alepis E, Solanas A, Patsakis C. Security and privacy analysis of mobile health applications: The alarming state of practice. IEEE Access. 2018;6:9390–9403.CrossRefGoogle Scholar
  14. 14.
    Grundy Q, Chiu K, Held F, Continella A, Bero L, Holz R. Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis. BMJ. 2019;364:l920.CrossRefGoogle Scholar
  15. 15.
    Grindrod K, Boersema J, Waked K, Smith V, Yang J, Gebotys C. Locking it down: The privacy and security of mobile medication apps. Can Pharm J. 2017;150(1):60–66.CrossRefGoogle Scholar
  16. 16.
    Blenner SR, Köllmer M, Rouse AJ, Daneshvar N, Williams C, Andrews LB. Privacy policies of android diabetes apps and sharing of health information. JAMA. 2016;315(10):1051–1052.CrossRefGoogle Scholar
  17. 17.
    Robillard JM, Feng TL, Sporn AB, et al. Availability, readability, and content of privacy policies and terms of agreements of mental health apps. Internet Interventions. 2019;17.CrossRefGoogle Scholar
  18. 18.
    Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Quality Health Care. 2007;19(6):349–357.CrossRefGoogle Scholar
  19. 19.
    Santo K, Richtering SS, Chalmers J, Thiagalingam A, Chow CK, Redfern J. Mobile phone apps to improve medication adherence: A systematic stepwise process to identify high-quality apps. JMIR mHealth uHealth. 2016;4(4):e132-e132.CrossRefGoogle Scholar
  20. 20.
    Android Developers. System permissions. 2018; https://developer.android.com/guide/topics/security/permissions.html#normal-dangerous. Accessed July 27, 2018.
  21. 21.
    Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.CrossRefGoogle Scholar
  22. 22.
    Google I. Play console help: Set up prices & app distribution. 2019; https://support.google.com/googleplay/android-developer/answer/6334373?hl=en&ref_topic=7071529. Accessed May 1, 2019.
  23. 23.
    Othman N, Vitry A, Roughead EE. Quality of pharmaceutical advertisements in medical journals: A systematic review. PLOS ONE. 2009;4(7):e6350.CrossRefGoogle Scholar
  24. 24.
    Korenstein D, Keyhani S, Mendelson A, Ross JS. Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLOS ONE. 2011;6(8):e23336.CrossRefGoogle Scholar
  25. 25.
    Day S, Zweig M.Beyond wellness for the healthy: Digital health consumer adoption 2018. San Francisco: Rock Health;2018.Google Scholar
  26. 26.
    Sunyaev A, Dehling T, Taylor PL, Mandl KD. Availability and quality of mobile health app privacy policies. JAMIA. 2015;22(e1):e28-e33.PubMedGoogle Scholar
  27. 27.
    Lupton D. The commodification of patient opinion: the digital patient experience economy in the age of big data. Sociol Health Illn. 2014;36(6):856–869.CrossRefGoogle Scholar
  28. 28.
    Lupton D, Jutel A. ‘It’s like having a physician in your pocket!’ A critical analysis of self-diagnosis smartphone apps. Soc Sci Med. 2015;133:128–135.CrossRefGoogle Scholar
  29. 29.
    Parker L, Grundy Q, Bero L. Interpreting evidence in general practice: Bias and conflicts of interest. Aust J General Practitioners. 2018;47(6):337–340.CrossRefGoogle Scholar
  30. 30.
    Pathirana T, Clark J, Moynihan R. Mapping the drivers of overdiagnosis to potential solutions. BMJ. 2017;358:j3879.CrossRefGoogle Scholar
  31. 31.
    Parker L, Bero L, Gillies D, et al. Mental health messages in prominent mental health apps. Ann Family Med. 2018;16(4):338–342.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  1. 1.Faculty of NursingUniversity of TorontoTorontoCanada
  2. 2.School of Pharmacy, Charles Perkins CentreThe University of SydneyCamperdownAustralia

Personalised recommendations